Paris, France

Eric Goupil

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Unither Pharmaceuticals. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eric Goupil: Innovator in Pharmaceutical Formulations

Introduction

Eric Goupil is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of medications. His innovative approach focuses on enhancing the delivery and efficacy of drugs.

Latest Patents

Eric Goupil holds a patent for a pharmaceutical formulation designed for administering paracetamol via the buccal or gingival route. This formulation consists of a hydroalcoholic solution containing dissolved paracetamol. The key characteristics of this invention include a paracetamol mass ranging from 95 mg to 190 mg, a hydroalcoholic solution volume between 1.0 ml and 2.0 ml, an alcohol degree between 48.5° and 52.5°, and a paracetamol concentration between 85 mg/ml and 110 mg/ml. This formulation aims to accelerate the speed at which paracetamol crosses the blood-brain barrier, making it particularly useful for treating pain or fever.

Career Highlights

Eric Goupil is associated with Unither Pharmaceuticals, a company known for its innovative approaches in the pharmaceutical industry. His work at Unither has allowed him to focus on developing advanced drug delivery systems that improve patient outcomes.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Eric Goupil's contributions to pharmaceutical formulations demonstrate his commitment to innovation in medicine. His patent for a novel paracetamol delivery system highlights the potential for improved therapeutic effects in pain management.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…